tert-butyl (3-(hydroxyamino)-3-oxopropyl)carbamate | 847780-39-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (3-(hydroxyamino)-3-oxopropyl)carbamate
• 英文别名: N-(tert-butoxycarbonyl)-β-alanine hydroxamic acid；tert-butyl N-[3-(hydroxyamino)-3-oxopropyl]carbamate
• CAS: 847780-39-6
• 化学式: C₈H₁₆N₂O₄
• mdl: MFCD24388915
• 分子量: 204.226
• InChiKey: MSUNUIUITMXBCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  87.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-叔丁氧羰基-BETA-丙氨酰氯 在 盐酸羟胺 、 potassium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 0.75h， 生成 tert-butyl (3-(hydroxyamino)-3-oxopropyl)carbamate
  参考文献：
  名称：

  使用通用氯化剂 CPI-Cl 从 Nα 保护的氨基酸合成 Nα 保护的氨基异羟肟酸

  摘要：

  已经在一锅中描述了使用多功能氯化试剂 CPI-Cl 从 N-保护的氨基酸合成 N-保护的氨基异羟肟酸。本协议已显示出对氨基甲酸酯保护基团（如 Boc、Cbz 和 Fmoc）的兼容性，并且氨基酸的侧链保护显示出完全的耐受性。

  DOI：

  10.24820/ark.5550190.p010.727

文献信息

• Compositions Having Antimycrobial Activity Including a Hydroxamate or a Hydroxamate and a Hydroxlyamine
  申请人：Kohn Harold

  公开号：US20080249181A1

  公开（公告）日：2008-10-09

  Antimycorbacterial compositions are disclosed comprising at least one hydroxamate or at least one hydroxamate and at least one hydroxylamine. The preferred ratio of hydroxamate to hydroxylamines is about 100:1 to about 1:1. A method for inhibiting mycobacterial growth is also disclosed comprising the step of administering the compositions of this invention to an animal including a human.

  公开了包含至少一种羟肟酸盐或至少一种羟肟酸盐和至少一种羟肟胺的抗分枝杆菌组合物。羟肟酸盐与羟肟胺的优选比例约为100：1至约1：1。还公开了一种抑制分枝杆菌生长的方法，包括将本发明的组合物给动物，包括人类。
• ANTIBODY-DRUG CONJUGATE HAVING ACIDIC SELF-STABILIZATION JUNCTION
  申请人：SICHUAN BAILI PHARMACEUTICAL CO. LTD.

  公开号：US20210100912A1

  公开（公告）日：2021-04-08

  The present invention provides a special drug conjugate having a hydrophilic acidic stabilization junction. Compared with a conjugate having a lower drug loading, due to the introduction of the acidic stabilization junction, the conjugate in the present invention can also have a higher drug loading (that is, each targeted reagent has more hydrophilic drug junctions), keeps a desired PK property and has a same or better activity in a body.
• US7662856B2
  申请人：——

  公开号：US7662856B2

  公开（公告）日：2010-02-16
• [EN] HYDROXAMIC ACID DERIVATIVES, PREPARATION AND THERAPEUTIC USES THEREOF<br/>[FR] DÉRIVÉS D'ACIDE HYDROXAMIQUE, PRÉPARATION ET UTILISATIONS THÉRAPEUTIQUES DE CEUX-CI
  申请人：KHAN AMIN

  公开号：WO2010065709A2

  公开（公告）日：2010-06-10

  Disclosed are amino alkyl/aryl hydroxamic acid compounds and pharmaceutical compositions containing such compounds. The disclosed compositions are useful as therapeutics for degenerative diseases in mammal.
• The synthesis of Nα-protected amino hydroxamic acids from Nα-protected amino acids employing versatile chlorinating agent CPI-Cl
  作者：U. Vathsala、C. Srinivasulu、L. Santhosh、Vommina V. Sureshbabu

  DOI：10.24820/ark.5550190.p010.727

  日期：——

  Racemization free synthesis of N-protected amino hydroxamic acids from N-protected amino acids employing the versatile chlorinating reagent CPI-Cl has been described in one-pot. The present protocol has shown compability towards urethane protecting groups like Boc, Cbz and Fmoc, and side chain protections of amino acids showed complete tolerance.

  已经在一锅中描述了使用多功能氯化试剂 CPI-Cl 从 N-保护的氨基酸合成 N-保护的氨基异羟肟酸。本协议已显示出对氨基甲酸酯保护基团（如 Boc、Cbz 和 Fmoc）的兼容性，并且氨基酸的侧链保护显示出完全的耐受性。